Back to PSX Analysis

The Searle Company Ltd. (SEARL:PSX)

Recent Price

PKR 112.06

(As of Oct 25, 2025)

Key Investor Metrics

Market Cap

65.92B

PKR

Forward P/E Ratio

17.01

vs 21.7 (Peers)

EPS (FY 2025)

0.85

PKR

Debt/Equity Ratio

0.24

Low Leverage

Financial Health & Performance

Searle's financial performance shows resilience. After a significant loss in 2024, the company returned to profitability in 2025. Revenue has seen a slight dip in 2025 after consistent growth, reflecting a challenging economic environment.

Shareholder Value & Dividends

Historically, Searle has rewarded shareholders with both cash dividends and bonus shares. The chart below shows the cash dividend percentage declared. In recent years (2022-2025), the focus has shifted towards bonus shares and reinvestment for growth.

PESTLE Analysis: Pharma Sector

The company operates within the complex Pakistani pharmaceutical landscape, influenced by several macro-environmental factors.

Political

  • Government drug pricing policies (DRAP).
  • Deregulation of non-essential drugs.
  • General political & economic stability.

Economic

  • PKR devaluation impacting import costs.
  • High inflation rates.
  • Reliance on imported raw materials (APIs).
  • Rising healthcare spending.

Social

  • Large and growing population.
  • Increasing health awareness & demand.
  • Preference for generic drugs.

Technological

  • Investment in R&D and biotech.
  • Adoption of modern manufacturing processes.
  • Need for technology transfer.

Legal

  • Strict regulatory framework (DRAP).
  • Patent laws and intellectual property rights.
  • Anti-corruption and transparency measures.

Environmental

  • Pharmaceutical waste disposal regulations.
  • Environmental manufacturing standards.
  • Focus on sustainable practices.

Future Outlook & Valuation

Analysts project strong future earnings growth. Based on forward P/E, the stock appears undervalued compared to its peers. However, the average analyst price target suggests a potential downside from its current price.

Forecast Revenue Growth

15.6% / annum

Forecast Earnings Growth

34.4% / annum

Analyst 12-Month Target

PKR 104.35